Bispecific antibodies: design, therapy, perspectives

Area of Science:

• Immunology
• Biotechnology
• Pharmacology

Background:

• Bispecific antibodies (BsAbs) are engineered molecules with two distinct antigen-binding sites.
• Interest in BsAbs has surged due to their therapeutic potential, with significant growth in publications over the last decade.
• The first therapeutic BsAb article was published in 1992, highlighting early exploration of their clinical utility.

Purpose of the Study:

• To review diverse methods for producing bispecific antibodies.
• To describe the characteristics of approved therapeutic BsAbs.
• To summarize the future prospects of novel BsAbs in various diseases.

Main Methods:

• Genetic engineering techniques for BsAb generation.
• Chemical conjugation strategies for BsAb development.
• Analysis of preclinical and clinical trial data for BsAb efficacy.

Main Results:

• Two BsAbs, catumaxomab (2009) and blinatumomab (2014), have been approved for therapeutic use.
• Recent research focuses on advanced production methods and diverse disease applications.
• Numerous preclinical and clinical trials are investigating the potential of new BsAbs.

Conclusions:

• Bispecific antibodies represent a rapidly advancing field with significant therapeutic promise.
• Continued innovation in production and clinical evaluation is expanding the application of BsAbs.
• BsAbs are poised to play an increasingly important role in treating various diseases.